Growing community of inventors

Nagoya, Japan

Tadahiko Inukai

Average Co-Inventor Count = 4.92

ph-index = 2

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 27

Tadahiko InukaiHideaki Yamada (2 patents)Tadahiko InukaiYasuko Yoshida (2 patents)Tadahiko InukaiMitsuo Kawase (2 patents)Tadahiko InukaiKuniyoshi Matsunaga (2 patents)Tadahiko InukaiKimiyasu Isobe (2 patents)Tadahiko InukaiShogo Otsuji (2 patents)Tadahiko InukaiTakaaki Hasegawa (2 patents)Tadahiko InukaiAkira Matsuura (1 patent)Tadahiko InukaiMichio Ohta (1 patent)Tadahiko InukaiKenichi Miyamoto (1 patent)Tadahiko InukaiMasayuki Nadai (1 patent)Tadahiko InukaiHiroyuki Sumi (1 patent)Tadahiko InukaiHisashi Mihara (1 patent)Tadahiko InukaiTadahiko Inukai (5 patents)Hideaki YamadaHideaki Yamada (72 patents)Yasuko YoshidaYasuko Yoshida (9 patents)Mitsuo KawaseMitsuo Kawase (9 patents)Kuniyoshi MatsunagaKuniyoshi Matsunaga (8 patents)Kimiyasu IsobeKimiyasu Isobe (5 patents)Shogo OtsujiShogo Otsuji (2 patents)Takaaki HasegawaTakaaki Hasegawa (2 patents)Akira MatsuuraAkira Matsuura (9 patents)Michio OhtaMichio Ohta (2 patents)Kenichi MiyamotoKenichi Miyamoto (1 patent)Masayuki NadaiMasayuki Nadai (1 patent)Hiroyuki SumiHiroyuki Sumi (1 patent)Hisashi MiharaHisashi Mihara (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Amano Seiyaku Kabushiki Kaisha (3 from 3 patents)

2. Other (2 from 832,912 patents)

3. Ngk Insulators, Inc. (1 from 4,924 patents)

4. Biseiken Co., Ltd. (1 from 1 patent)


5 patents:

1. 6395717 - Therapeutic drug for endotoxin blood symptom and multi-organ failure induced thereby

2. 6083931 - Method of inhibiting cancer metastasis

3. 4617263 - Method for quantitative determination of acetylputrescine in a mixture

4. 4568545 - Thrombolytic agent

5. 4550078 - Method for the quantitative determination of individual polyamine

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
1/8/2026
Loading…